# Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

> **NCT06552559** · PHASE1,PHASE2 · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 37 (estimated)

## Conditions studied

- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
- CNS Metastases

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT06552559
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06552559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06552559, "Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06552559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*